Yi Larson
Director/Board Member bij OLEMA PHARMACEUTICALS, INC.
Vermogen: - $ op 31-03-2024
Profiel
Mevrouw Yi Larson is een onafhankelijk bestuurder bij Olema Pharmaceuticals, Inc. Zij zetelt in de Raad van Bestuur van Olema Pharmaceuticals, Inc. en Rayzebio, Inc. Mevrouw Larson was voorheen werkzaam als Chief Financial Officer & Executive Vice President bij Turning Point Therapeutics, Inc. Zij behaalde haar bachelor diploma aan The Wharton School van de Universiteit van Pennsylvania, een graduaat diploma aan het Massachusetts Institute of Technology en een MBA aan The Wharton School van de Universiteit van Pennsylvania.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
LIANBIO
-.--% | 10-04-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
16-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Yi Larson
Bedrijven | Functie | Begin |
---|---|---|
OLEMA PHARMACEUTICALS, INC. | Director/Board Member | 06-04-2021 |
Eerdere bekende functies van Yi Larson
Bedrijven | Functie | Einde |
---|---|---|
RAYZEBIO, INC. | Director/Board Member | 26-02-2024 |
LIANBIO | Director of Finance/CFO | 19-12-2023 |
TURG POIN | Director of Finance/CFO | 31-03-2021 |
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Corporate Officer/Principal | - |
Opleiding van Yi Larson
Massachusetts Institute of Technology | Graduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
OLEMA PHARMACEUTICALS, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
LIANBIO | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Finance |